1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Lacutamab Data Boost Prospects For Innate Pharma

Potential Cutaneous T-Cell Lymphoma Therapy

 
• By Kevin Grogan

The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.

Marseilles
Marseilles is home to Innate Pharma • Source: Shutterstock

Having suffered a setback in the summer with its AstraZeneca PLC-partnered asset monalizumab, there is a lot riding on Innate Pharma S.A.'s lacutamab and initial mid-stage data on the French biotech's drug have proved promising.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.